THE AFRICAN AMERICAN HEART STUDY
PARTNER FOR SUCCESS WITH THE ASSOCIATION OF BLACK CARDIOLOGISTS AS STUDY SITES AND PARTICIPANTS
You Can Make a Difference!
The African American Heart Study
The observational African American Heart Study will investigate the association between lipoprotein(a) and atherosclerotic cardiovascular disease in 5,000 African American participants in the U.S.
GLOBAL PRINCIPAL INVESTIGATOR:
Elizabeth Ofili, MD, MPH, FACC
Sponsor: Amgen
If you are interested in participating as a clinical site, please complete this form.
| HEART STUDY’S GOAL: Better Understand and Serve the Underrepresented The African American Heart Study aims to provide insights into the association between lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease (ASCVD) risk in African Americans, a population historically underrepresented in research. |
STUDY RATIONALE
High Lp(a) levels are associated with incident ASCVD, but research has primarily been conducted on individuals of European descent. Information on the association between Lp(a) levels with incident ASCVD in persons of African descent is lacking. Lp(a) levels differ by race/ethnicity and are highly heritable, largely genetically determined, and unaffected by health behaviors. The African American Heart Study consists of self-identified African American, Black, or African-descent participants with ASCVD at enrollment (cases) and self-identified African American, Black, or African-descent participants without ASCVD at enrollment (controls) from cardiology and primary care practices. Real-world data (RWD) will be used to retrospectively characterize and prospectively follow cases and controls for at least 3 years. The primary objectives are to estimate the association between Lp(a) molar concentration and the presence of ASCVD at enrollment, to characterize sequence variants associated with Lp(a) molar coWncentrations, and to characterize sequence variants associated with the presence of ASCVD at enrollment. The key secondary objective is to estimate associations between Lp(a) molar concentration, sequence variants, and clinical factors with cardiovascular events during at least three years of RWD follow-up, separately among participants with and without ASCVD at enrollment. The other (non-key) secondary objectives are to describe comorbidity and medication burden among individuals with and without ASCVD at enrollment.
OVERALL DESIGN
This study will enroll approximately 2,500 self-identified African American cases with ASCVD at enrollment and 2,500 self-identified African American controls without ASCVD at enrollment from cardiology and primary care practices across the US. The Health 360xTM platform will be used to screen practice electronic health records (EHR) and identify eligible cases and controls. Health 360x is a chronic disease and population health management platform. Patients report their health data to the platform (i.e., blood glucose, blood pressure, cholesterol, and weight). Doctors and coaches connected to the patients have an opportunity to review and interact with patients on Lp(a) data returned from the study. Health 360x also has integrations with 1upHealth to pull EHR data from health systems across the country. Health 360x integrates into the CRIO clinical trial management system. Once patients are identified, have provided consent, and populated in CRIO, Health 360x will support the aggregation of their EHR data and review of results (inclusion criteria for study). In addition, Health 360x will support downstream data aggregation and submission to deCODE, a subsidiary of Amgen with extensive expertise in genetic analyses. An enrollment visit includes a physical examination, weight, height, waist circumference, blood pressure measurements, completion of a questionnaire, and blood samples. Retrospective EHR and claims data will be used to characterize participants at enrollment. Prospective follow-up will be solely through events identified via linked EHR, claims data, and death records.
KEY INCLUSION CRITERIA
♥ Self-reported race as Black, African American, or of African descent
♥ 18-85 years of age at enrollment
♥ Matched 1:1 ASCVD case to control on age (+/- 3 years at enrollment), sex, and recruitment site
• ASCVD cases require the presence of ASCVD, defined as a diagnosis or procedure code indicating a history of Myocardial Infarction (MI), coronary or lower
• extremity arterial revascularization, or significant coronary artery disease without prior revascularization at or prior to enrollment
• Controls are participants free of ASCVD codes at or prior to enrollment
| If you are interested in participating as a clinical site, please complete this form. |
Please access key publications, articles, and other relevant information:
♥ American Heart Association. African Americans and Heart Disease, Stroke. Available at the American Heart Association website.
♥ CDC. Lipoprotein (a). Available at the Centers for Disease Contol and Prevention website.
♥ Kronenberg F, et al. Eur Heart J. 2022; 43:3935-3946.
♥ Reyes-Soffer G, et al. Arterioscler Thromb Vasc Biol. 2022;42:e48-e60.
♥ Tsimikas S, et al. J Am Coll Cardiol. 2017;69:692-711.
♥ Tsimikas S, et al. J Am Coll Cardiol. 2018;71:177-192.
♥ Tsimikas S, et al. J Am Coll Cardiol. 2022;80:934-946.
♥ Virani, SS, et al. Prog Cardiovasc Dis. 2022;73:32-40.
♥ Wilson DP, et al. J. Clin Lipidol. 2019;13:374-92.
| Health 360x Clinical Research Platform for Scalable Access to Clinical Trials is funded by the National Center for Advancing Translational Science, National Institutes of Health, Small Business Innovation Research Award # 5R44TR003832 (PI Chamberlain Obialo, MD, Accuhealth Technologies, Inc.) The content of the Press Release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
Click the Image Below to Download the Flyer
